Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $39.00 at Truist Financial

Posted by Francis Steltz on Aug 8th, 2026

Viridian Therapeutics (NASDAQ:VRDN – Free Report) had its target price increased by Truist Financial from $38.00 to $39.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

Several other brokerages also recently weighed in on VRDN. Weiss Ratings downgraded Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wells Fargo & Company upgraded Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $31.00 in a report on Monday, June 29th. The Goldman Sachs Group reiterated a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a research report on Monday, June 29th. Finally, Evercore set a $26.00 price target on Viridian Therapeutics in a research note on Friday, May 15th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.93.

Read Our Latest Stock Report on VRDN

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $23.59 on Friday. The stock has a market capitalization of $2.43 billion, a P/E ratio of -7.00 and a beta of 0.91. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The firm’s 50-day moving average is $18.38 and its two-hundred day moving average is $21.67.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). The firm had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%. Equities analysts predict that Viridian Therapeutics will post -3.87 earnings per share for the current year.

Insider Buying and Selling at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the completion of the acquisition, the director owned 5,090,928 shares of the company’s stock, valued at $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Viridian Therapeutics

A number of institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC raised its stake in shares of Viridian Therapeutics by 108.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares during the period. Morgan Stanley lifted its stake in shares of Viridian Therapeutics by 805.6% during the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after purchasing an additional 1,546,284 shares in the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Viridian Therapeutics in the fourth quarter worth about $46,680,000. Vanguard Group Inc. grew its stake in shares of Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after buying an additional 1,280,161 shares in the last quarter. Finally, Commodore Capital LP raised its holdings in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after buying an additional 1,275,000 shares during the period.

About Viridian Therapeutics

(Get Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.